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Abstract
Introduction
Red blood cell (RBC) transfusions can be a life-saving and important intervention
used to replace blood loss or manage anemia, but they also come with risks from
transfusion-associated adverse events (TAAEs). Patient blood management (PBM)
involves a multidisciplinary approach to optimize care of patients who may need a
transfusion, including blood conservation modalities, patient-centered decision making,
among others. The impact of PBM in the pediatric setting is not well understood,
particularly the impact on TAAEs and the economic impact of these programs.
The following specific aims were pursued: (1) To investigate the effect of a PBM
program on transfusion utilization and the incidence of TAAEs, and (2) to compare the
costs related to supporting a health-system level PBM program to the costs of transfusion
utilization.
Methods
This study used a retrospective cohort design to evaluate the impact of a PBM
program on patient outcomes in a pediatric hospital system. Clinical and demographic
information from pediatric patients between the ages of four months and eighteen years
who had an inpatient hospitalization were compared for the year prior to the program
(2015) and the year post-implementation (2019). Transfusion utilization was compared
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before and after the program using generalized estimating equation. A cost-benefit
analysis examined program costs and compared them to program outputs.
Results
This study examined a total of 35,245 hospitalizations and over 3,800 transfusions
in the pre- and post-intervention years. The post-intervention year had lower pretransfusion hemoglobin values and smaller volumes of RBC transfusions ordered, and
this was statistically significant (p<0.01). While this study did not see a statistically
significant difference in the incidence of TAAEs, fewer hospitalizations had RBC
transfusions ordered in 2019 when compared to 2015. When examining transfusion
utilization while adjusting for potential confounders, group year was not statistically
significant (p = 0.11). Overall, activity-based transfusion costs based on projections were
higher in the post-intervention year.
Conclusion
This study explored the impact of a PBM program on pediatric hospitalized
patients at a large tertiary academic medical center. The results suggest that this work
was effective in reducing the mean hemoglobin pre-transfusion for RBC transfusion and
reduced the mean volume of transfusion when adjusted for severity of illness and length
of stay. The results of the cost-benefit analysis suggest that this investment in safety did
not correspond with decreased utilization costs, but there were limitations in the analysis.
More research is needed to understand the impact of reductions in transfusion-associated
adverse events and their true cost.

Keywords: patient blood management, transfusion safety, cost-benefit analysis
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Summary of Study
Patient blood management is a strategy for optimizing transfusion, but there have
been limited studies evaluating a larger patient blood management program in pediatrics.
The research protocol for this study was approved on April 12, 2021, by Baylor
College of Medicine Institutional Review Board and December 7, 2021, by the
University of Texas Health Science Center at Houston Committee for the Protection of
Human Subjects with Baylor College of Medicine serving as the IRB of record. An
appropriate data use agreement was obtained between both institutions. This study sought
to investigate the effect of a patient blood management program on transfusion utilization
and the incidence of transfusion-associated adverse events, and to compare the costs
related to supporting a health-system level patient blood management program to the
costs of transfusion utilization.
There were no changes to the proposal, but internal salary data related to the
personnel costs of the program was not available, and therefore external estimates were
used.
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Cost-Benefit Analysis of a Pediatric Patient Blood Management Program
Blood transfusions are used to quickly restore oxygen carrying capacity due to
acute blood loss from injury or trauma-induced coagulopathy. Though transfusions are a
crucial intervention in the context of trauma and treatment of hematologic and oncologic
diseases, the balance of risk to benefit must be carefully considered. Transfusionassociated adverse events can cause clinically significant complications, including fatal
reactions and the Joint Commission identified blood transfusion as one of the top
overused interventions or treatments (Joint Commission, 2012). Transfusion-related
adverse events can be the result of physiologic response to the blood components being
transfused but also a result of system-level aspects of transfusion management (Delaney
et al., 2016). Pediatric patients have twice the incidence of transfusion-related adverse
events compared to adults, at a rate of 6.2 reactions per 1,000 transfusions (Oakley,
Woods, Arnold, & Young, 2015).
Unfortunately, some of the physiologic mechanisms of transfusion reactions are
not entirely understood. Certain patients may have a higher risk for transfusion reactions,
notably patients who have received transfusions before who may have developed
antibodies that elicit allergic responses, or as a result of immunosuppression with donor
cells attacking the host (Delaney et al., 2016). More commonly, transfusion reactions are
a result of errors in the collection, storage, or administration process (Bolton-Maggs,
2017). The Serious Hazards of Transfusion (SHOT) hemovigilance program in the
United Kingdom found that “error-related reports account for 87% of all notifications”
(Bolton-Maggs, 2017, p. 395) to the data collection program. Some examples of system-
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level reported causes of transfusion reaction include transfusing an incompatible blood
component to a patient or transfusing too much volume to induce circulatory overload.
In response to these potentially preventable transfusion-related adverse events,
hemovigilance programs began in France in the 1990s to improve the quality and safety
of the blood product supply chain from the donor to recipient in response to the HIV
crisis (Jain & Kaur, 2012). Initially, the focus centered on surveillance to quantify
transfusion-related adverse events and soon broader patient blood management
interventions arose from that initial effort to focus on transfusion in the context of clinical
care of patients (Jain & Kaur, 2012). Patient blood management (PBM) is defined as an
“evidence-based, multidisciplinary approach to optimizing the care of patients who might
need transfusion” (Joint Commission, 2019). PBM includes a variety of interventions
surrounding the decision to transfuse, including “patient evaluation and clinical
management…application of appropriate indications, as well as minimization of blood
loss and optimization of patient red cell mass” (Joint Commission, 2019, p. 5). The
Society for the Advancement of Blood Management demonstrates in their organizational
chart that the combination of interdisciplinary blood conservation modalities, patientcentered decision making, optimization of coagulation, and management of anemia can
lead to improved patient outcomes (Goobie et al., 2019, p. 223). These interventions can
include restrictive hemoglobin thresholds for transfusion of red blood cell products,
transfusion guidelines, massive transfusion protocols, among others (Goobie et al., 2019).
From the beginning of 2016 through the end of 2018, several interventions were
undertaken as a part of a larger patient blood management program. In November 2015, a
Transfusion Safety Officer (TSO) was hired to focus on transfusion safety throughout the
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system. The orientation process for that role meant that the TSO did not begin
implementing interventions until 2016. Clinical decision support interventions began with
weight-based dosing for red blood cell transfusions in June 2016. Shortly after,
development on an evidence-based guideline with a multidisciplinary team began in
October 2016. This process included a forty-member multidisciplinary team with a
thorough literature review, recommendations using the GRADE methodology
(Schünemann et al., 2013), and was finalized with system-wide communication and
provider education that began in January 2018 and was completed in March 2018.
Positive patient identification through a blood product administration module in the
health record allowed for additional safety checks and data collection. The objective is to
investigate the effect of this patient blood management program on transfusion utilization
and the incidence of transfusion-related adverse events and to compare costs to benefits
of the program. During this four-year time period, several service line specific initiatives
took place that would shift the location of care from the inpatient setting to the outpatient
setting in an infusion center and a critical care tower opened.
The hypothesis of this study is that these interventions will cause reduced
utilization of pediatric red blood cell transfusion and an increased incidence of
transfusion reaction from increased awareness and improved recognition. This is
anticipated to lead to reduced costs throughout the system.
Specific Aims
To test the central hypothesis, the following specific aims will be pursued:
1.

To investigate the effect of a patient blood management program on

transfusion utilization and the incidence of transfusion-related adverse events.
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2.

To compare the costs related to supporting a health-system level patient

blood management program to the costs of transfusion utilization.
Significance and Innovation
Significance
Effectiveness of patient blood management has been investigated in both adult
and pediatric patients. A systematic review of patient blood management interventions in
adult patients undergoing surgery found that “comprehensive anemia management,
minimizing iatrogenic blood loss,” along with the optimization of the “patient-specific
physiological balance of trauma” (Althoff et al., 2019, p. 794) did reduce the number of
patients exposed to allogenic red blood cell transfusion, number of units per allogenic red
blood cell transfusions per patient, length of hospital stay, total number of complications,
and mortality. The finding in this meta-analysis was consistent through several categories
of surgery and incorporated seventeen studies of over 235,000 patients. National level
programs, such as the SHOT hemovigilance program, have improved reporting of
transfusion reactions and improved overall safety (Bolton-Maggs, 2017).
When looking more closely at specific interventions that fall under the larger
umbrella of patient blood management, several interventions have been shown to
maintain or improve patient outcomes while minimizing risk from or exposure to
transfusion in pediatrics. One of these interventions includes standardizing the
hemoglobin level at which a transfusion is indicated. Lacroix et al. (2007) conducted the
first randomized controlled trial to evaluate transfusion thresholds in critically ill
pediatric patients and demonstrated non-inferiority of lower hemoglobin thresholds to
higher thresholds with respect to mortality. Red blood cell transfusion threshold studies
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have been repeated in pediatric patients with sepsis (Karam et al., 2011), pediatric
patients with burns (Voigt et al., 2018), and most recently pediatric cardiac surgery
patients (Deng et al., 2019). Given the overall infrequent incidence of transfusionassociated adverse events, these studies had sample sizes too small to identify the impact
of hemoglobin thresholds on transfusion reactions and primarily focused on other patient
outcomes such as mortality, transfusion utilization, and other related clinical outcomes.
In looking at the role of laboratory monitoring, a Cochrane systematic review and
meta-analysis also found few studies evaluating viscoelastic monitoring, namely
thromboelastography (TEG) and rotational thromboelastometry (ROTEM), for trauma
induced coagulopathy in adult trauma patients (Hunt et al., 2015). After analyzing the
findings of the three studies found in the review, Hunt et al. (2015) failed to demonstrate
the utility of ROTEM or TEG when evaluating diagnostic accuracy, but they noted the
need for research to evaluate the utility of these tests further.
Other promising patient blood management interventions include the use of
antifibrinolytic medications or factor prothrombin complex concentrates to reduce blood
loss or minimize transfusion requirements. The CRASH-2 Trial was a randomized
controlled trial comparing tranexamic acid to placebo in adult trauma patients and found
that early treatment reduced both the risk of death and demonstrated cost effectiveness
but did not have an impact on blood products transfused (Roberts et al., 2013). In
pediatrics, tranexamic acid has been associated with decreased mortality in trauma
(Eckert et al., 2014), but transfusion utilization or adverse events have not been studied
well in trauma. Tranexamic acid has been shown to reduce transfusion requirements in
other pediatric surgical procedures associated with significant blood loss, namely
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scoliosis surgery (Johnson et al., 2017) and craniofacial surgery (Basta, Stricker, &
Taylor, 2012). In adult studies, four factor prothrombin complex concentrate has been
demonstrated to improve survival (Zeeshan et al., 2019) and has shown reduction of
bleeding and lower red blood cells transfused in both pediatric and adult surgical patients
(Fominskiy et al., 2016). Although these adult studies have demonstrated the utility of
antifibrinolytic drugs such as tranexamic acid or human factor concentrate replacements,
the impact on pediatric trauma patients is still unknown.
Clinical decision support systems in the electronic health record are another way
of encouraging prudent transfusion ordering as well as checking for safety. A study
evaluating the impact of clinical decision support at the point of ordering on transfusion
utilization in a large hospital system targeted to adult patients, suggested that clinical
decision support was able to save approximately $1.6 million in red blood cell purchase
costs (Goodnough et al., 2014). Clinical decision support demonstrates the opportunity to
not only reduce unnecessary exposure to transfusion, but to also potentially save the
healthcare system operational costs as well.
Interventions in pediatric patients are generally less studied compared to most
interventions in the adult population. As children have different mechanisms of injury
and physiologic responses to trauma than adults, in addition to the general aspects of
child growth and development, adult studies are insufficient to guide care decisions.
Although some evidence exists in related pediatric populations, one should not assume
that the effect is similar in the context of pediatric care. Economic analyses of
transfusion-related events have been performed on the population level in Spain (RibedSánchez et al., 2018), Australia (Trentino et al., 2015), and the Netherlands (Janssen et
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al., 2018) for adults. De-Gast Bakker et al. (2013) looked at cost of transfusion in a
randomized, controlled trial on restrictive compared to liberal transfusion strategies in
pediatric patients undergoing surgery for congenital cardiac defects. Although the authors
investigated the impact of cost, they only incorporated the cost of transfusions and was
not powered to investigate transfusion-related adverse events. Randomized controlled
trials are not the ideal design to evaluate the impact of an infrequent clinical scenario,
even one associated with high morbidity, mortality, and cost. To date, an economic
evaluation of a patient blood management program in pediatric patients has not yet been
published.
Innovation
A large cohort study with patients of varying clinical conditions will help
strengthen our understanding of the impact of patient blood management in pediatric
patients. Due to the infrequent incidence of transfusion reactions, smaller studies were
not powered to investigate differences between groups. This proposal is innovative
because this approach evaluates the effects of patient blood management on an entire
health system from a population level rather than the impact of a single test or
intervention. In healthcare, many approaches to problems include complex interventions.
By using large data sets from a large pediatric health system, the research would be able
to reach statistical power to be able to detect changes in the incidence of transfusionrelated adverse events and evaluate the impact on charges related to transfusion
administration and transfusion-related adverse events that the earlier studies were not
able to evaluate. Currently, most studies in the context of transfusion only evaluate a
single intervention or in a very specific patient population, and this study is one of the
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first studies to assess patient blood management program in a large pediatric population.
In addition, this research will add to the growing body of literature on optimization of
RBC transfusion in pediatric patients, potentially leading to de-implementation, or “the
process of identifying and removing harmful
Conceptual Framework
The World Health Organization Conceptual Framework for the International
Classification for Patient Safety (2009) serves as the foundation for this study (see Figure
1), with a focus on quantifying the harms related to the transfusion. Given limitations in
measuring other aspects of the framework, this proposal centers around patient-centered
outcomes. Within this framework, transfusion-related adverse events are identified as a
healthcare-associated harm that have further downstream effects not only on patient
outcomes, but also on organizational outcomes and quality. From a system-level, early
detection, and mitigating factors will subsequently impact true harm to the patient. The
goal for quality and safety work is to achieve the triple aim: improving the quality of care
delivered, improving population health, and reducing health care costs (Berwick et al.,
2008). As the cost implications for a larger program of patient blood management has not
been performed in a pediatric population, the objective is to evaluate the impact of these
programs in this setting.
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Figure 1
The World Health Organization Conceptual Framework for the International
Classification for Patient Safety (WHO, 2009).
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Approach
Study Design, Sample, and Setting.
This investigation will utilize a retrospective cohort design to analyze clinical and
demographic data from the electronic health record (EPIC, Verona, WI) and from Blood
Bank records. Pediatric patients from the age of four months to the age of eighteen years
at the time of the encounter will be included if they were hospitalized in a large pediatric
health system with hospital encounter discharge dates between January 1, 2015 to
December 31, 2019.
Measurements for Aim #1: To investigate the effect of a patient blood
management program on transfusion utilization and the incidence of
transfusion-related adverse events.
To establish the impact of the program, the transfusion utilization and incidence
of transfusion-related adverse events from 2015 (the pre-intervention year) will be
compared to those in 2019 (the maintenance phase). The following patient-specific data
elements will be extracted from the electronic data warehouse within the electronic health
record (Epic; Verona, WI) for patients whose encounter discharge dates were between
January 1, 2015 and December 31, 2015 for the pre-intervention group and January 1,
2019 to December 31, 2019 for the post-intervention group. Clinical and demographic
information will be collected to compare the baseline characteristics between the two
groups. The patient data that will be collected includes the patient’s medical record
number, encounter number, date of birth, sex, race/ethnicity, payor status, date of hospital
encounter, date of hospital discharge, weight in kilograms, ICU length of stay, hospital
length of stay, severity of illness (3M™ APR DRG Classification System), transfusion
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administration during the hospitalization, and presence of trauma team activation (CPT
code G0390). The patient’s medical record number will be used to identify multiple
hospitalizations during the time period. If the patient received a transfusion, additional
data elements will include date of transfusion(s), previous hemoglobin level prior to each
administration of the transfusion, volume of red blood cell unit(s) or milliliters (mL),
total volume and numbers of red blood cell units transfused during the admission,
location of administration of transfusion(s) (i.e. emergency room, inpatient units, or
critical care units), and incidence of transfusion-related adverse events. To investigate
transfusion-associated adverse events, the following transfusion-associated adverse
events will be included: transfusion-related acute lung injury, transfusion-associated
circulatory overload, acute or delayed hemolytic transfusion reactions, anaphylactic
transfusion reactions, transfusion-transmitted bacterial infection, immunologic
transfusion reactions (urticaria) and febrile non-hemolytic transfusion reaction. Presence
of adverse events will be identified through the diagnosis code for transfusion reactions
of any kind, specifically ICD-9 and ICD-10 codes since the transition of coding systems
spanned the duration of the study. All cases will be cross-referenced with Transfusion
Safety records through the Blood Bank. All the different types of adverse events will be
analyzed under the broad characterization of adverse events. If sufficient power is
achieved, specific adverse events will be analyzed individually by the respective ICD-9
and ICD-10 codes.
Measurements for Aim #2: To compare the costs related to supporting a healthsystem level patient blood management program to costs of transfusion
utilization.
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For the purposes of the economic evaluation of the program, this analysis will assume
the perspective of the hospital system. The program inputs that will be measured will
include personnel costs, equipment and materials, and training time specifically related to
the patient blood management work. For personnel estimations, the salary for transfusion
safety officer for the duration of the intervention (November 2015 to December 2019)
will be included. To preserve privacy, the median salary for an advanced practice
provider will be included for the analysis of salary costs. For those with only intermittent
participation in these events, the salaries with estimated hours of effort for the guideline
and clinical decision support development, including the guideline methodologist, Epic
analyst, and salary of those physicians and nurses involved in the development and
review for the duration of meetings and document review. No additional facility indirect
costs were considered as significant growth occurred during this time period with the
opening one community hospital and a critical care tower as it could not be specifically
attributed to the patient blood management program alone. The increase in transfusion
medicine physician staff and infrastructure was primarily to support the coagulation
program. The training time for the staff based off hourly wage for nurses from human
resources and the overall number of nurses who completed the online training and time to
complete that module. Physician training did not occur outside of regular academic
meetings and will not be included in this estimate. Salary data will be obtained from
human resources and generalized to the role of the specific team members.
To evaluate the program outputs, the costs of acquisition of a red blood cell
transfusion will be estimated along with estimates of the direct and indirect costs. For the
cost of a single transfusion, the acquisition price for one unit of packed red blood cells
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that covered the donation center’s cost for collecting, processing, and testing for each unit
will be calculated and multiplied by the number of transfusions for 2015 and 2019,
including partial units for infants and smaller children. The average cost of one unit of
red cells for the years 2015 and 2019 will be acquired from the institution’s blood bank
records, along with number of units dispensed in those years. Estimates for direct and
indirect costs will be calculated from previous research and adjusted for inflation the
respective years. Shander et al. (2010) found activity-based costs for a blood transfusion
from four US hospitals to average between $760 per unit transfused (2010, p. 759). The
range of values will be used for sensitivity analyses, using the range of $522 and $1183,
adjusted for inflation each calendar year to quantify the uncertainty around the estimates
of the effect (Shander et al., 2010, p. 759).
Procedure for Data Collection.
The protocol will be submitted to IRB for review at both the University of Texas
Health Science Center and Baylor College of Medicine prior to initiation with a request
for a waiver of consent. The electronic health record will be queried for the data
elements. To ensure that the elements of the data request are correct, a random selection
of charts will be used to validate the data extracted by manual chart review. All data will
be stored in a password protected folder on a protected server with the University of
Texas Health Science Center at Houston.
Risk & Benefit to the Subjects.
The level of risk that this proposal subjects the participants to is minimal. As this
study is a query of previously collected data, patients will not require any additional
encounters for data collection. After the data are extracted from the electronic health
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record and data validation is complete, the data will be de-identified using an assignment
by another code and assigning age at admission rather than using birth date. Data will be
stored on a password protected drive to ensure no loss of patient privacy where only the
principal investigator and the dissertation committee will have access to the data. Staff
information such as salary costs will be hosted on the same secure servers to maintain
participant privacy. For staff salary information, privacy will be maintained by using the
median salary for that job classification rather than direct figures.
Patients have the potential to benefit from the results of this study as the findings
of the study could help healthcare professionals better understand the effect of safety
programs implemented in a hospital system.
Data Analysis Plan for Aim 1.
Aim 1: To investigate the effect of a patient blood management program on
transfusion utilization and the incidence of transfusion-related adverse events.
Data analysis will be done using IBM SPSS Statistics v. 24.0 (Armonk, NY).
Significance will be set to p<.05 using two-sided tests. Baseline clinical and demographic
information will be presented as summary statistics and reported for the pre-intervention
year of the program (2015) and the sustainability phase of the program (2019).
Generalized estimating equation will be used to evaluate the proportion of hospital
encounters where the patient received red blood cell transfusions in 2015 compared to
2019. Poisson regression will be used to evaluate the differences in incidence of
transfusion-related adverse events in patients with transfusions. Linear regression will be
used to evaluate the hemoglobin level prior to transfusion. Covariates for those analyses
will include patients with multiple admissions during the specified time period, age,
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severity of illness, massive transfusion protocol activations, ICU length of stay, and
overall length of stay.
Data Analysis Plan for Aim 2.
Aim 2: To compare the costs related to supporting a health-system level patient
blood management program to the costs of transfusion utilization.
Regarding the cost evaluation, direct and estimated indirect costs of the programs
will be compared and historical data from 2015 will be used to project utilization and will
assume that without focused interventions, red blood cell transfusion utilization will
continue at that rate. Total direct and estimated indirect program costs and outputs will be
calculated for the pre-intervention phase and the maintenance phase. Utilization
projections of rate ratios of transfusion from the first year of measurement (prior to the
program kickoff) will be compared to the final year of the program to evaluate for
differences in transfusion administration charges and charges for treatment related to
transfusion reaction using χ2 tests. Variance adjustment will be applied for correlation
between multiple admissions for the same patient, age, overall length of stay, ICU length
of stay, and overall length of stay.
Potential Pitfalls and Limitations
As this proposal describes a retrospective data collection, there is potential for
error by not prospectively collecting data which may mean that some patient events or
costs may be missed. To ensure data validity, findings from the electronic health record
query will be verified with other reporting systems used for regulatory requirements. A
selection of charts will be reviewed manually to safeguard from potential data errors in
the code written for the query from the patient level data. Although the proposal may
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miss some unidentified potential confounding factors, the design includes relevant factors
identified from previous studies in this area as baseline demographic and clinical data.
For the economic evaluation, as the cost data was not collected prospectively, the
estimated values may not reflect the actual costs incurred by the program nor the outputs,
but the estimation of uncertainty will provide a range of values that would be expected.
Another potential pitfall includes that during the intervention, a large critical care
tower opened in May of 2018, increasing the number of critically ill children that were
admitted to the hospital. By using ICU admission as a potential covariate, this potential
confounder can be controlled for in the analysis. Since this analysis excludes outpatient
transfusions, this approach will exclude the transition of care from the inpatient to
outpatient settings that has occurred between 2015 and 2019. As transfusion reactions are
estimated to be under-identified, there is a potential limitation in identifying all cases, but
the cases identified by diagnosis codes will be cross referenced with the actively
collected data collected by the Blood Bank on transfusion reactions.
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Introduction
Red blood cell (RBC) transfusions are used to replace blood loss from traumatic
injury and otherwise improve the oxygen carrying capacity from anemia that results from
iatrogenic or other identified causes. RBC transfusions are commonly used in the
management of trauma, hematologic and oncologic diseases, and in the context of
surgery and were identified as one of the top overused interventions or treatments (Joint
Commission, 2012). As with most medical interventions, potential lifesaving benefits are
mitigated by the potential risks. RBC transfusion-associated adverse events, ranging from
mild reactions to death, can be the result of physiologic response to the blood
components being transfused or result of system-level aspects of transfusion management
(Delaney et al., 2016). Pediatric patients have twice the rate of transfusion-associated
adverse events (TAAEs) when compared to adult patients, with a rate of 6.2 per 1,000
transfusions (Oakley, Woods, Arnold, & Young, 2015).
Physiologic mechanisms for transfusion reactions are not entirely understood,
with some patients inherently having a higher risk for TAAEs. Some known risk factors
include patients who have received transfusions before who may have developed
antibodies that elicit allergic responses or immunosuppression with donor cells attacking
the host (Delaney et al., 2016). While physiologic responses to transfusion account for a
portion of TAAEs, an overwhelming majority of TAAEs are a result of system-level
errors in the collection, storage, or administration process of transfusing blood products
(Bolton-Maggs, 2017). Error-related reports account for 87% of all notifications (BoltonMaggs, 2017, p. 395) to the Serious Hazards of Transfusion (SHOT) hemovigilance
program in the United Kingdom. Transfusing incompatible blood components, excessive
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transfusion volumes that result in fluid overload, and transfusion-associated infections
from donor blood components are examples of system-level reported causes of TAAEs.
In the 1990s, France began hemovigilance programs that were intended to ensure
the safety of the blood product supply chain from the donor to recipient in response to the
HIV crisis (Jain & Kaur, 2012). Surveillance to quantify TAAEs were the initial focus of
these efforts, and eventually broadened to include not only activities within the blood
bank, but also in the context of clinical care of patients (Jain & Kaur, 2012). From these
efforts, patient blood management (PBM) emerged as an “evidence-based,
multidisciplinary approach to optimizing the care of patients who might need
transfusion” (Joint Commission, 2019). PBM includes several interventions surrounding
the decision to transfuse, including “patient evaluation and clinical
management…application of appropriate indications, as well as minimization of blood
loss and optimization of patient red cell mass” (Joint Commission, 2019, p. 5). The
combination of interdisciplinary blood conservation modalities, patient-centered decision
making, optimization of coagulation, and management of anemia can lead to improved
patient outcomes (Goobie et al., 2019, p. 223). Some PBM interventions can include
restrictive hemoglobin thresholds for transfusion of RBC products, transfusion
guidelines, massive transfusion protocols, among others (Goobie et al., 2019).
This study sought to investigate the effect of a PBM program on transfusion
utilization and the incidence of TAAEs in a pediatric population and to compare the costs
related to supporting a health-system level PBM program to the costs of transfusion
utilization. The hypothesis of this study is that these PBM interventions will cause
reduced utilization of pediatric RBC transfusion, an increased incidence of TAAEs from
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increased situational awareness, and that the benefits of this program will outweigh the
costs. The following specific aims were pursued:
1. To investigate the effect of a patient blood management program on transfusion
utilization and the incidence of transfusion-associated adverse events.
2. To compare the costs related to supporting a health-system level patient blood
management program to the costs of transfusion utilization.
Background
Currently health services research in the realm of patient blood management and
hemovigilance has identified strategies to reduce exposure to unnecessary transfusions
and has shown some success in adult hospital settings (Leahy, Hofmann, Towler, et al.,
2017; Warner, Schaefer, Madde, et al., 2019). In adult patients undergoing surgery,
Althoff and colleagues found that “comprehensive anemia management, minimizing
iatrogenic blood loss,” along with the optimization of the “patient-specific physiological
balance of trauma” (Althoff et al., 2019, p. 794) reduced the number of patients exposed
to allogenic red blood cell transfusion, number of units of red blood cell transfusions per
patient, length of hospital stays, total number of complications, and mortality. These
findings were consistent through several categories of surgery and incorporated seventeen
studies of over 235,000 patients. The SHOT hemovigilance program and other national
level hemovigilance programs have improved both reporting of transfusion reactions and
overall transfusion safety (Bolton-Maggs, 2017).
Several interventions under the larger concept of PBM have been shown to
maintain or improve pediatric patient outcomes while minimizing risk from or exposure
to transfusion, including reducing the hemoglobin threshold that triggers transfusion,
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viscoelastic monitoring, antifibrinolytic administration, and using clinical decision
support to support clinical decision-making.
With respect to standardizing the hemoglobin level at which a transfusion is
indicated, a systematic review and meta-analysis indicated that reduced transfusion
thresholds can reduce exposure to RBC transfusion without changes in mortality or
morbidity in adults (Carson et al., 2021). Lacroix et al. (2007) conducted the first
randomized controlled trial to evaluate transfusion thresholds in critically ill pediatric
patients. Lacroix and colleagues (2007) demonstrated non-inferiority of lower
hemoglobin thresholds to higher thresholds with respect to mortality. RBC transfusion
thresholds have been studied in many other pediatric populations, including pediatric
patients with sepsis (Karam et al., 2011), pediatric patients with burns (Voigt et al.,
2018), and pediatric patients undergoing cardiovascular surgeries (Cholette, et al. 2011,
Deng et al., 2019). Unfortunately, pediatric studies to date have been underpowered to
determine the impact of transfusion thresholds on TAEEs.
Several laboratory assays have been evaluated for their applicability to PBM.
Viscoelastic monitoring is a point of care whole blood test that provides insight into the
kinetics of an individual’s clotting process, from formation through breakdown (Sayce,
Neal, & Leeper, 2020). A systematic review and meta-analysis also found few studies
evaluating thromboelastography (TEG) and rotational thromboelastometry (ROTEM),
two types of viscoelastic monitoring, for trauma-induced coagulopathy in adult trauma
patients (Hunt et al., 2015). Hunt and colleagues (2015) failed to demonstrate the utility
of ROTEM or TEG when evaluating diagnostic accuracy but called for further research
due to limitations in numbers of studies and concerns regarding risk of bias.
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Other promising PBM interventions include using antifibrinolytic medications or
factor prothrombin complex concentrates to reduce blood loss or minimize transfusion
requirements. The CRASH-2 Trial was a randomized controlled trial comparing
tranexamic acid (TXA) to placebo in adult trauma patients and found that early treatment
reduced both the risk of all-cause mortality and death related to bleeding (CRASH-2 Trial
Collaborators, 2013). The CRASH-2 Trial also demonstrated the cost effectiveness of
TXA but did not demonstrate a reduction on blood products transfused (Roberts et al.,
2013). In pediatrics, TXA has shown a similar effect with decreased mortality in trauma
patients (Eckert et al., 2014). Unfortunately, transfusion utilization and TAAEs have not
been studied well in trauma, likely due to small sample sizes. TXA has been evaluated in
other pediatric surgical procedures associated with significant blood loss, namely
scoliosis surgery (Johnson et al., 2017) and craniofacial surgery (Basta, Stricker, &
Taylor, 2012) and was found to reduce transfusion requirements in both populations. In
adult studies, four factor prothrombin complex concentrate (PCC) has been demonstrated
to improve survival (Zeeshan et al., 2019) and has shown a reduction of bleeding and
reduced transfusions in both pediatric and adult surgical patients (Fominskiy et al., 2016).
While adult studies have demonstrated the utility of antifibrinolytic drugs such as TXA or
PCCs, the impact on pediatric trauma patients has not been established in the research.
PBM has both patient-level interventions, as described earlier, and systems-level
interventions, such as clinical decision support (CDS) systems in the electronic health
record (EHR). CDS can be used to encourage prudent transfusion ordering through
information displayed at the point of care or linking to relevant references for the
clinician. Many EHRs also have alert functionality that can be used to support safety
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systems for potential errors in dosing and administration. For example, alerts may notify
a clinician when a transfusion was ordered if the patient’s hemoglobin is higher than the
threshold or provide brief education at the point of order entry. A large-scale study that
sought to evaluate the impact of an alert at the point of ordering on transfusion utilization
in a large hospital system targeted to adult patients found that CDS was able to save
approximately $1.6 million in red blood cell purchase costs (Goodnough et al., 2014).
CDS may be an effective tool to reduce unnecessary exposure to transfusion, but to also
save the healthcare system operational costs as well.
Unfortunately, interventions in pediatric patients are generally less studied
compared to most interventions in the adult population. With respect to trauma, children
have different mechanisms of injury and physiologic responses to trauma than adults
along with variations due to growth and development. Often, adult studies are insufficient
to guide care decisions for pediatric patients. Economic analyses of TAAEs have been
performed on the population level for adults in a variety of countries, including Spain
(Ribed-Sánchez, et al., 2018), Australia (Trentino et al., 2015), and the Netherlands
(Janssen et al., 2018). In one of the randomized, controlled trials that looked at restrictive
transfusion strategies in pediatric patients undergoing surgery for congenital cardiac
defects, De-Gast Bakker et al. (2013) looked at cost of transfusion, but they only
incorporated the cost of transfusions and was not powered to investigate TAAEs.
Randomized controlled trials are not the ideal design to evaluate the impact of infrequent
harms, and many studies evaluating the efficacy of PBM interventions are underpowered
to detect differences in risk of harms. To date, a system-wide economic evaluation of a
patient blood management program in pediatric patients has not yet been published.
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Conceptual Framework
This study design was influenced by the World Health Organization Conceptual
Framework for the International Classification for Patient Safety (2009) (Figure 1). In
this framework, system level concepts are integrated to describe the complexity of patient
safety. This framework incorporates contributing factors such as the incident type, patient
and incident characteristics, mitigating factors, detection, and how actions can be taken
by individuals and health systems to reduce risk.
Methods
Design
A retrospective cohort design was used to evaluate the impact of the patient blood
management program. Clinical and demographic data were extracted from the electronic
health record (Epic®, Verona, WI) for pediatric patients between the ages of four months
to eighteen years at the time of the hospital encounter.
To complete the economic analysis, a cost-benefit analysis approach was used
from the perspective of the hospital system. Program inputs evaluated included personnel
costs, equipment and materials, and training time related to the PBM work for the period
of the PBM intervention period of 2015 to 2019.
Human Subjects Protections
This study was approved by the Baylor College of Medicine Institutional Review
Board and the University of Texas Health Science Center Committee for the Protection
of Human Subjects. A Data Use Agreement between Baylor College of Medicine and the
University of Texas Health Science Center at Houston was obtained to utilize data
collected from the electronic health record at Texas Children’s Hospital, which has an
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academic affiliation with Baylor College of Medicine. Reciprocity between academic
organizations was obtained with Baylor College of Medicine Institutional Review Board
being the IRB of record for this study.
Sample and Setting
This study was conducted at a large quaternary pediatric hospital health system in
the greater Houston metropolitan area. The health system serves a large southeast Texas
region and has a total of three hospitals that care for pediatric patients and pregnant
people in both the inpatient, outpatient, and community settings. A pediatric patient blood
management program that consisted of a transfusion safety officer role, an evidencebased multi-disciplinary guideline with electronic health record clinical decision support,
and a structured education program for physicians and nurses was implemented
beginning in 2016. A number of PBM interventions along with EHR blood product
administration and additional clinician education took place between 2016 and 2018. For
the purposes of this analysis, the patients who were discharged in the calendar year of
2015 were used as the pre-intervention year, and the patients discharged in 2019 were
analyzed as the post-intervention year. While PBM refers to all aspects of blood
transfusion, including all fractionated blood components and whole blood administration,
this analysis will focus only on RBC transfusions given that was the primary focus of the
interventions in this time period.
To evaluate the impact of the patient blood management program, pediatric
patients who were between the ages of four months to eighteen years at the date of
admission to the hospital were included. Infants under four months were excluded from
this analysis due to physiologic differences in vitamin K-dependent clotting factors and
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maternal antibodies being present making the approach to transfusion different than with
older children (Lau, 2017). Patients who were admitted for short-term stays under
observation status, patients who only presented to the emergency center and were
discharged home without admission, and those who only were in the hospital for surgical
procedures without admission were excluded. Patients were included in the analysis if
they were discharged from their hospital admission between January 1, 2015, and
December 31, 2015, for the pre-intervention group and discharged between January 1,
2019, and December 31, 2019, for the post-intervention group.
For the purposes of this analysis, this cost benefit analysis adopted the perspective
of the direct and indirect costs related to the PBM program were compared to the costs of
transfusion utilization. Program inputs in the form of personnel costs and training time
related to the PBM work were compared with program outputs of costs of transfusion.
Procedure for Data Collection
After receiving approval, data were extracted through the electronic health record
electronic data warehouse. Subjects were identified through a query from the electronic
data warehouse for all patients admitted to Texas Children’s Hospital and divided into
two groups: those who were discharged between January 1, 2015, to December 31, 2015,
and those who were discharged between the dates of January 1, 2019, and December 31,
2019. Clinical and demographic were obtained for those patients, and if the patients had a
transfusion ordered during the admission, additional information about the transfusion
volume, hemoglobin prior to the RBC administration, and others was collected.
For the economic analysis, median and salary range data were collected from the
occupational employment and wage statistics from the United States Bureau of Labor
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Statistics Occupational Employment and Wage Statistics May 2021 Metropolitan and
Nonmetropolitan Area Occupational Employment and Wage Estimates: Houston-The
Woodlands-Sugar Land, TX (2022). Each of the roles that participated in the guideline
development process and transfusion safety work were queried from the reports for the
Houston-The Woodlands-Sugar Land region as defined by the OEWS survey, which
includes Austin, Brazoria, Chambers, Fort Bend, Galveston, Harris, Liberty,
Montgomery, and Waller counties. Reported 10th percentile, median, and 90th percentile
salaries were obtained for the roles involved in this geographic area.
Measurements
Transfusion Utilization
For each hospitalization of patients who were discharged in the 2015 and 2019
groups, the following information was collected: medical record number, hospital
encounter number, date of birth, sex, race/ethnicity, payor status, date of hospital
encounter, date of hospital discharge, weight in kilograms, intensive care unit (ICU)
length of stay, hospital length of stay, severity of illness, (3M™ APR DRG Classification
System), and if the patient had a charge for a transfusion administration during the
hospitalization.
For the patients who received a transfusion during those time frames, additional
information was collected from the EHR. For each transfusion, the date of the transfusion
was collected, volume of red blood cell unit(s) or milliliters (mL), total volume and
numbers of red blood cell units transfused during the admission, hemoglobin level within
twenty-four hours prior to the transfusion order, volume of the transfusion, patient
weight, and if the patient had a diagnosis code that indicated they experienced a TAEE.
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The following TAEEs were evaluated using International Classification of Diseases
(ICD) codes: transfusion-related acute lung injury, transfusion-associated circulatory
overload, acute or delayed hemolytic transfusion reactions, anaphylactic transfusion
reactions, transfusion-transmitted bacterial infection, immunologic transfusion reactions
(urticaria) and febrile non-hemolytic transfusion reaction. Presence of trauma team
activation from the CPT code was not consistently identified in key cases and therefore
was not used in this analysis.
Economic Analysis of Hospital-Based PBM Interventions
To estimate the inputs of the program, salaries and estimated hours of efforts for
those involved in the PBM work were calculated. This calculation includes the salaries of
the following roles and their time estimated that was dedicated to PBM interventions:
transfusion safety officer, guideline methodologist, EHR analyst, and multidisciplinary
team used to develop the guideline and implement the associated CDS. No additional
indirect costs were considered as significant growth occurred during this period in which
another community hospital and critical care tower opened in this hospital system. The
indirect costs related to increasing capacity of transfusion medicine service line could not
be directly attributed to the PBM program and therefore were excluded from this
analysis. Capital costs of the EHR blood product administration module were not
available and were not included in this analysis. Additional costs included the training
time for staff. These costs were estimated off nursing hourly wage and the overall
number of nurses who completed the online training and time to complete that module.
Since physician training did not occur outside of regular academic meetings, it was not
included in this estimate.
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Transfusion cost estimates were estimated using the number of transfusions
administered during the pre- and post-intervention years with activity-based costing.
Shander et al. (2010) found activity-based costs for a blood transfusion from four US
hospitals to average $760 per unit transfused (2010, p. 759). The range of values will be
used for sensitivity analyses, using the range of $522 and $1183, adjusted for inflation to
quantify the uncertainty around the estimates of the effect (Shander et al., 2010, p. 759).
All costs were adjusted to 2021 using the US Consumer Price Index (U. S. Bureau of
Labor Statistics, n.d.) so that direct comparisons of transfusion costs could be compared
with salary estimates. Because Shander et al. (2010) adjusted their activity-based cost
analysis for 2008, for this study, an inflation rate of 32.5% was used according to the
U.S. Consumer Price Index when comparing costs between December 2008 and
December 2021 (Bureau of Labor Statistics, n.d ). This resulted in using the following
estimates for the activity-based costs: $1007.90 as an average cost per unit transfused
with a range of $692.27 to $1568.88 per unit transfused.
Statistical Analysis
SPSS® (version 27, SPSS Inc., Chicago, IL) software was used for data analysis.
Significance was set to p<0.05 using two-sided tests. Clinical and demographic data were
analyzed using summary statistics for the pre-intervention year of the program (patients
who were discharged in 2015) and the sustainability phase of the program (including
patients who were discharged in 2019) using chi-squared tests and independent samples ttests. Generalized estimating equation was used to evaluate the relationship between
transfusion utilization using covariates of illness severity, ICU length of stay, and overall
length of stay.
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For the cost evaluation, direct and estimated indirect costs of the programs were
compared and historical data from 2015 were used to project utilization and will assume
that without focused interventions, red blood cell transfusion utilization will continue at
that rate. Utilization projections of rates of transfusion per 10,000 hospitalizations and
rates of transfusions per 10,000 hospital days from the first year of measurement (prior to
the program kickoff) was compared to the final year of the program to evaluate for
differences in transfusion administration costs.
Results
Patient Blood Management Intervention
Study Population Characteristics
A total of 35,245 hospital admissions were analyzed in this study. Of those
admissions, 16,519 hospitalizations were characterized as the pre-PBM intervention
group (discharged in 2015) and 18,726 in the post-PBM intervention group (discharged
in 2019). Within each of these groups, there were 11,970 unique patients in the 2015 year
and 13,459 unique patients in 2019. Demographic information of each group is presented
in Table 1 and baseline clinical characteristics are listed in Table 2.
When comparing the characteristics of the admissions, the mean age at admission
for both groups was seven years of age and slightly less than half of admissions were of
female patients. A total of 41.6% of admissions identified as Hispanic or Latino (with
41.1% in 2015 and 42.1% in 2019).
Transfusion Administration
Of the 16,519 hospitalizations in 2015, 1,854 of those hospitalizations had RBC
transfusions administered during the stay (11.22%). The post-intervention year saw
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roughly the same number of transfusions, with transfusions administered during 1,960
hospitalizations of the 18,726 total (10.47%). As a surrogate measure to estimate RBC
transfusion guideline recommendation adherence, volume of RBC transfusion
administration and pre-transfusion hemoglobin level were analyzed (see Table 3).
A total of 11,423 transfusions were analyzed further, specifically to compare the
mean volume of transfusion volume administered and the pre-transfusion hemoglobin
level between the pre- and post-intervention years. In 2015, the mean volume ordered for
an RBC transfusion was 10.81 ± 6.19 mg/kg (n=4,877 transfusion). In 2019, this value
was reduced to a mean of 9.09 ± 4.41 mg/kg (n = 6,527 transfusions) and this difference
was statistically significant using an independent samples t-test (t8372 = 16.537; p < 0.05).
When looking at the mean hemoglobin in the 24 hours prior to transfusion, the
mean hemoglobin levels in 2015 group were 7.77 ± 1.57 g/dL compared to 7.34 ± 1.48
g/dL in the 2019 group. This difference was statistically significant using an independent
samples t-test with equal variances assumed (t9043= 13.436, p < 0.05).
Transfusion Reaction
A total of 25 transfusion reactions were identified in this sample, with 10
occurring in 2015 and 15 in 2019. This difference of incidence of transfusion reactions
was not statistically significant (χ2 = 0.47, df = 1, p=0.49). See Table 4 for details of the
transfusion reactions on both the pre- and post-intervention years.
Transfusion Utilization
To explore the relationship between transfusion utilization between the pre- and
post-intervention groups, generalized estimating equation was used with the severity
level as a categorical factor and covariates of total days in ICU and overall length of stay.
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In this model, overall length of stay and severity level were significant predictors of
transfusion utilization (see Table 5). In the model, increasing level of severity
(categorized by the 3MTM APR DRG Severity of Illness Level) led to increasing
likelihood of having a transfusion during that administration (p < 0.05). The year and
whether or not the hospitalization included ICU care were not statistically significant in
the model (p = 0.105 and p= 0.08, respectively).
Economic evaluation
Program inputs
Salaries costs were the primary program input evaluated in this study and
included staff salaries and estimated hours to the project. Detailed information regarding
salary cost calculations per individual role is presented in Table 6. Percentiles of the
pediatrician salaries were not available from the United States Bureau of Labor Statistics
Occupational Employment and Wage Statistics May 2021, but minimum and maximums
are presented in Table 6 using the 10th and 90th percentiles of other staff and median
estimates for pediatricians. Median estimates for pediatricians were used for overall
salary inputs costs given that ranges were unavailable. Including all the different
participants for the guideline development and transfusion safety work, program inputs
totaled to $355,863. Using a range of 10th and 90th percentiles for salary to provide a
sensitivity analysis, these estimated costs ranged from $318,361 and $464,866.
Outputs transfusion
Activity-based cost estimates for transfusion were taken from Shander et al.
(2010) and were adjusted for inflation to be comparable with salary estimates to 2021.
Since Shander and colleagues’ (2010) analysis was reported in 2009 dollars, these were
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adjusted to be comparable with 2021 wage data with an 32.5% inflation rate between
December 2008 and December 2021 according to the U.S. Consumer Price Index (U.S.
Bureau of Labor Statistics, n.d.). As such, the activity-based costs were as follows for an
RBC transfusion: minimum $692.27; mean $1007.90; maximum: $1568.88. See Table 7
for detailed information regarding activity-based cost estimates for the pre- and postintervention groups. Using these estimates, transfusion activity-based costs averaged
$4,917,544 in 2015 (range $3,377,585 to $7,654,566) and $6,595,698 in 2019 (range
$4,530,215 to $10,266,751).
Transfusions per hospitalization were calculated by the total number of
transfusions ordered divided by the number of hospitalizations for the pre- and postintervention groups. To create a comparable measure, these estimates were multiplied by
10,000 admissions and activity-based costs were calculated using previously described
estimates that were adjusted for inflation (Shander et al, 2010). Details about the
estimates for the rates can be seen in Table 8 for calculations based on hospital
admissions. To account for the differences in length of stay between the years,
transfusions per 10,000 patient days were calculated and details can be found in Table 9.
Activity-based costs based on number of transfusions per 10,000 hospital
admissions were higher in the 2019 cohort than in the 2015 cohort. This resulted in an
overall increase of $245,273 (with a range of $374,518 to $848,764). When looking at
transfusions per 10,000 patient days, this persisted with 44 more transfusions per 10,000
patient days and an increased cost as well. This difference was estimated to be an
increase of $44,544 (range $30,595 to $69,337) per 10,000 patient days. These
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Discussion
This study described transfusion practices during hospital admissions for pediatric
patients and evaluated the impact of PBM interventions on RBC transfusion utilization,
transfusion-associated adverse events, and the overall economic impact. Overall, hospital
admissions increased notably between the pre- and post-intervention years with more
hospitalizations that included ICU care . While this study found increased costs related to
transfusion administration when looking at the number of transfusions ordered, fewer
overall hospitalizations had RBC transfusions administered during their stay, lower
volumes of RBCs were ordered per transfusion, and there was a lower hemoglobin value
prior to the RBC transfusion being ordered.
As pediatric patients use weight-based dosing for medications and transfusion
volumes, the volume of transfusion ordered and pre-transfusion hemoglobin are
surrogates for understanding guideline adherence since the guideline and CDS explicitly
made recommendations in this area. This study found statistically significant reductions
in both the volume of transfusion and the pre-transfusion hemoglobin. While the mean
difference is fairly small, this large sample size indicates that it is likely that the PBM
work reduced exposure to transfusion through reducing the volume ordered at a time with
CDS. Unfortunately, it was not possible to identify those who had decided against
ordering a transfusion after reading the CDS at the time of order entry. Despite those
limitations, the data show a reduction which suggests overall guideline adherence.
An increase in absolute numbers of transfusion associated circulatory overload
were identified in the post-intervention group. As the overall mean volume of transfusion
per kilogram of body weight decreased in the post-intervention group, this increase may

39
be attributable to the increase in situational awareness, recognition, and reporting rather
than an increase in incidence.
This study failed to demonstrate that a PBM program was effective in reducing
transfusion utilization at the hospitalization level when controlling for potentially
confounding factors such as severity of illness, overall length of stay, and ICU admission.
While this study identified increased costs of the program and increased absolute number
of transfusions, the economic impact of potentially avoidable TAAEs was not able to be
established. It is also possible that PBM program costs can not be recovered in the time
frame used in this study.
In looking to the economic literature, the estimates using adjusted rates for
activity-based costing were not too different from those included in Burns and colleagues
(2019) for outpatient transfusion-related costs in Australia. While Burns and colleagues
(2019) noted a lower total per unit costs of $659.59, this finding occurred in a public
health service country, which theoretically could reduce costs through a public health
system when compared with the United States. Other areas with public health systems
such as the United Kingdom have identified lower transfusion costs (Stokes et al., 2018).
When looking at the cost-effectiveness program, the findings of this study differ
when comparing to other programs. While Indelen and colleagues (2021) included
different costs in their estimation compared with this study, they found an overall costeffectiveness of a transfusion improvement program in Turkey in adult patients and noted
a decrease in the number of transfusions as a result of this work. Consistent with the
findings of Leahy et al. (2017), this PBM program also resulted in a reduced mean pretransfusion hemoglobin level and decreased volume of transfusion. This study did not
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find an overall cost-effectiveness when compared to Leahy and colleagues (2017), but it
is notable that their analysis compared the number of red cell units issued with the
denominator of total population regionally that the hospitals served in a public healthcare
system.
Strengths and Limitations
This study’s strengths include the volume of hospitalizations evaluated across a
health system, where prior research was limited in the pediatric population and relied on
large health system data that included adult patients or in smaller, more focused pediatric
studies.
There are several potential limitations to the study. First, with any retrospective
data, there were challenges in characterizing sub-populations that may require more
transfusions or that may be at higher risk for transfusion reactions given the nature of the
data collected in the EHR. For example, while many patients who are being treated for a
hematologic or oncologic disorder and are more likely to need a transfusion are often
admitted on the hematology/oncology floor or have their transfusion ordered by a
hematologist or oncologist, this practice is not universally true. Billing data, while more
easily available, often lacks the nuance that would give us a richer picture. We also know
that transfusion reactions are under-identified with passive reporting systems (Sahu &
Bajpai, 2020, Hendrickson, et al.2016; Raval, et al., 2015), and this limitation is possible
in this sample as well.
Given those limitations, the use of additional variables such as the 3MTM APR
DRG Severity of Illness score, ICU length of stay, and overall length of stay were used as
proxy variables. This study also excluded transfusions that were given in outpatient
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settings such as the emergency center, infusion center, or clinic, as many of the PBM
interventions were primarily targeting the inpatient settings.
Changes in the process as a result of the PBM efforts also added challenges to the
data analysis. As a result of the PBM initiatives, several improvements were made to the
EHR during the intervention period between 2016 and 2018 to improve provider
transfusion ordering and nursing documentation. Given these differences, the ordering
volume was used for the analysis, and although not all transfusions are given in their
entirety, an overwhelming majority of them are.
For the economic analysis, there were several limitations. The costs were
estimated retrospectively and not collected in real time, and therefore some of the hourly
contributions may have been under- or over-estimated. Also, the capital costs of the
software to implement the blood transfusion administration module within the EHR were
not available, and therefore were not included in this analysis. Another limitation is that a
major component of PBM is avoidance of TAAEs, which were not incorporated in this
analysis because no activity-based costing estimates exist for pediatric TAAEs. Future
research is needed in this area to better understand the economic impact of TAAEs in
pediatrics.
Implications for Research and Practice
With the increasing focus on preventing patient harm, clinicians and researchers
need to better understand the impact of PBM on pediatric patient outcomes. This research
adds to the growing body of literature on optimization of RBC transfusion in pediatric
patients. Further research could help us better identify how to support de-implementation
of over-used interventions, or “the process of identifying and removing harmful and low-
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value practices based on tradition and without scientific support” (Upvall & Bourgault,
2018, p. 379). Excess transfusion either through administering RBC transfusions when
other methods to address anemia could be used, administering higher RBC transfusion
volumes when not indicated, or other transfusion practices may be inadvertently causing
harm to patients.
To better understand the economic impact of these interventions, pediatric
researchers can further explore the activity-based costs for pediatric transfusions.
Currently, there are no recent estimates for pediatric red blood cell transfusion activity
costs which can take a significant amount of time for both nursing and the blood bank to
prepare and administer the transfusion, observe responses, and intervene for any
reactions. While this study estimated costs retrospectively, future research could gather
these costs prospectively to better estimate the cost of these programs and compare them
to patient outcomes. Another area of economic research includes the impact of pediatric
transfusion reactions. This study quantified the overall incidence in hospitalized pediatric
patients in a large system, but the economic impact is not well understood. While current
estimates in the United States are not available, Ribed-Sanchez and colleagues (2018)
have estimated the economic and social costs of adverse events associated with blood
transfusions in Spain and Janssen and colleagues (2018) estimated these costs based off
expert opinion in the Netherlands. Future research could quantify these for pediatric
patients in the United States health context.
Conclusion
Patient blood management programs use interdisciplinary interventions to
optimize transfusion with the intent to reduce unnecessary exposure to blood products
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and promote patient safety (Goobie et al., 2019). This study explored the impact of a
PBM program on pediatric hospitalized patients at a large tertiary academic medical
center. The results suggest that this work was effective in reducing the mean hemoglobin
pre-transfusion for RBC transfusion and reduced the mean volume of transfusion when
adjusted for severity of illness and length of stay. The results of the cost-benefit analysis
suggest that this investment in safety did not correspond with decreased utilization costs.
More research is needed to understand the impact of reductions in transfusion-associated
adverse events and their true cost.
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Figure 1
World Health Organization Conceptual Framework for the International Classification
for Patient Safety

Note. This figure is from the World Health Organization. (2009).
https://www.who.int/patientsafety/implementation/taxonomy/conceptual_framework/en/
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Table 1
Sociodemographic Characteristics of Hospitalizations
Sociodemographic
Characteristics
Number of Hospital
Admission
Unique Patients
Mean age at
admission (years)
Gender
Female
Male
Ethnicity
Hispanic or
Latino
Not Hispanic or
Latino
Race
American Indian
and Alaska
Native
Asian
Black of African
American
Hispanic or
Latino
Native Hawaiian
and other Pacific
Islander
White
Payor
Commercial
In-State Medicaid
Medicare
Other
Government
Other Payor
Self-pay
Tricare

Pre-PBM
Intervention
Group (2015)
16519

Post-PBM
Intervention
Group (2019)
18726

Total

11970

13459

7.14 (SD 5.65)

7.2 (SD 5.67)

7864 (47.6%)
8652 (52.4%)

8877 (47.4%)
9833 (52.5%

16741
18485

6784 (41.1%)

7880 (42.1%)

14664

9380 (56.8%)

10469 (55.9%)

19849

p value

35245

p = 0.33
p = 0.05

p =0.126

p <0.01
54 (0.3%)

78 (0.4%)

132

811 (4.9%)
3212 (19.4%)

918 (4.9%)
3938 (21%)

1729
7150

1 (<0.1%)

2 (<0.1%)

3

22 (0.1%)

37 (0.2%)

59

12066 (73%)

13244 (70.7%)

25310

6956 (42.1%)
5786 (35.5%)
59 (0.4%)
2978 (18%)

8030 (42.9%)
4050 (21.6%)
55 (0.3%)
5484 (29.3%)

14986
9836
114
8426

133 (0.8%)
444 (2.6%)
163 (1%)

208 (1.1%)
665 (3.6%)
234 (1.2%)

321
1109
397

p <0.01
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Note. Gender, ethnicity, and race are self-reported upon admission. SD = standard
deviation.
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Table 2
Clinical Characteristics of Hospitalizations
Pre-PBM

Post-PBM

Clinical

Intervention Group

Intervention Group

Characteristics

(2015)

(2019)

n = 16519

n = 18726

6.75 (SD 20.79)

7.1 (SD 20.05)

p = 0.1

3

3

p = 0.8

3056 (18.50%)

4513 (24.10%)

p < 0.01

0.91 (SD 5.55)

1.46 (SD 8.56)

p < 0.01

4.9 (12.11)

6.02 (16.62)

p = 0.01

2

3

p = 0.2

p value

Length of Stay
in days+ (mean)
Length of Stay
in days
(median)
Admission
included ICU
Stay^ n (%)
Total Days in
ICU across
groups (mean)
Total Days in
ICU for only
with ICU flag
(mean)
Total Days in
ICU (median)

57
3M APR DRG

p < 0.01

Severity of
Illness Level
Extreme

2344 (14.12%)

2485 (13.28%)

Major

4698 (28.46%)

5119 (27.35%)

Moderate

5654 (34.25%)

6969 (37.25%)

Minor

3812 (23.09%)

4138 (22.12%)

1854 (11.22%)

1960 (10.47%)

p = 0.02

10 (0.54%)

15 (0.77%)

p = 0.49

Transfusion
ordered during
hospitalization^
Experienced
Transfusion
Reaction?

Note. SD, Standard deviation
+

Statistically significantly different using 2-sided independent samples t-test with p <

0.05.
^ Statistically significantly different using 2-sided χ2 with p < 0.05.
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Table 3
Clinical characteristics of transfusion
Pre-PBM

Post-PBM

Clinical

Intervention Group

Intervention Group

Characteristics

(2015)

(2019)

p value

Pre-transfusion

mean

SD

mean

SD

7.78

1.57

7.34

1.48

p < 0.01

10.81

6.19

9.09

4.41

p < 0.01

hemoglobin
(mg/dL)*
Volume of
transfusion
(mL/kg)*
Note. SD, Standard deviation
* p<0.05 for independent samples t-test.
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Table 4
Frequency of transfusion reactions
Transfusion Reaction

Pre-PBM Intervention Group

Post-PBM Intervention

(2015)

Group (2019)

ABO incompatibility

1

0

Anaphylactic reaction

1

0

2

5

2

7

0

1

1

1

3

3

due to administration
of blood and blood
products
Febrile non-hemolytic
transfusion reaction
Transfusionassociated circulatory
overload
Transfusion-related
acute lung injury
Vascular
complications
following transfusion
Unspecified
transfusion reaction
Note. Some patients had multiple transfusion reactions in 2019.
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61

62

63
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Table 7
Activity-Based Transfusion Actual Cost Estimates
Transfusions Hospitalizations

Cost Min

Cost

Cost Max

($USD)

Mean

($USD)

($USD)
Pre-PBM
Intervention

4879

16519

3,377,585 4,917,544

7,654,566

6544

18726

4,530,215 6,595,698 10,266,751

Group (2015)
Post-PBM
Intervention
Group (2019)
Note. Activity-based cost estimates for transfusion were taken from Shander et al. (2010)
and were adjusted for inflation to be comparable with salary estimates to 2021 (costs
were reported in 2008 $USD). With an assumed 32.5% inflation rate between 2008 and
2021, the activity-based costs were as follows: (minimum $692.27; mean $1007.90;
maximum: $1568.88).
Reference: Shander, A., Hofmann, A., Ozawa, S., Theusinger, O. M., Gombotz, H., &
Spahn, D. R. (2010). Activity-based costs of blood transfusions in surgical patients at
four hospitals. Transfusion, 50(4), 753–765. https://doi.org/10.1111/j.15372995.2009.02518.x
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Table 8
Projected Activity-Based Cost Estimates per Admissions

Pre-PBM

Transfusions

Estimated

Estimated

Estimated

per 10,000

Minimum

Mean Cost

Maximum

admissions

Cost ($USD)

($USD)

Cost ($USD)

2,953

2,044,273

2,976,329

4,632,903

3,494

2,418,791

3,521,603

5,481,667

+541

374,518

545,273

848,764

Intervention Group
(2015)

Post-PBM
Intervention Group
(2019)

Calculated
difference between
2015 and 2019

Note: Activity-based cost estimates for transfusion were taken from Shander et al. (2010)
and were adjusted for inflation to be comparable with salary estimates to 2021 (costs
were reported in 2008 $USD). With an assumed 26.3% inflation rate between 2008 and
2021, the activity-based costs were as follows: (minimum $692.27; mean $1007.90;
maximum: $1568.88).
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Outstanding Nurses of 2022 Honoree, Texas Nurses Association District 9, 2022.
Nursing Excellence Award: Nurse with an Advanced Degree of the Year, Texas
Children’s Hospital, 2022.
PhD Student Award, Sigma Theta Tau Zeta Pi Chapter, 2022.
Excellence in Nursing Award Bronze Medalist, Good Samaritan Foundation, 2022.
FUNDED GRANTS
1. Pediatric Nurses’ Experiences in Caring in the Time of COVID: A qualitative
study. Sigma Theta Tau Zeta Pi Chapter Evidence Based Practice and
Research Award, $1,000, Co-Principal Investigator.
2. Hospitalized and Hungry: A Qualitative Study Assessing the Efficacy of an
Inpatient Food Insecurity Intervention Among Immigrant Families. Dr. Hema
Desai Pediatric Hospital Medicine Research Pilot Funding Award, $5,000,
Co-Investigator.
PUBLISHED MANUSCRIPTS
Tubbs-Cooley, H. L., Lavin, R., Lyndon, A., Anderson, J., Baernholdt, M., Berry, P.,
...Gibbs, K.D. ... Friese, C. R. Stronger together: The case for multidisciplinary tenure
track faculty in academic nursing. Nursing Outlook.
https://doi:10.1016/j.outlook.2021.03.016.
Gibbs, K. D., Shi, Y., Sanders, N., Bodnar, A., Brown, T., Shah, M. D., & Hess, L. M.
(2021). Evaluation of a Sepsis Alert in the Pediatric Acute Care Setting. Applied Clinical
Informatics, 12(3), 469–478. https://doi.org/10.1055/s-0041-1730027
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PUBLISHED MANUSCRIPTS
Crane, S., Gibbs, K. D., Nosich, R., Yang, Y., & Pawelek, E. (2021). Challenges in the
implementation of electronic systems for patient report of symptoms in oncology: a
scoping review. Journal of Hospital Management and Health Policy.
https://doi.org/10.21037/jhmhp-20-108
Lea, N. C., Gibbs, K., Johnson, C., Lam, A., Wuestner, E., & Hui, S. R. (2022).
Transfusion-Associated Adverse Events: A Case Report of Nurse Hemovigilance and
Recognition of Respiratory Distress. Journal of infusion nursing : the official publication
of the Infusion Nurses Society, 45(5), 264–269.
https://doi.org/10.1097/NAN.0000000000000483
Gibbs, K. D., Jones, J. T., LaMark, W., Abdulmooti, S., Bretz, L., Kearney, K. D.,
Narendorf, S. C., & Santa Maria, D. M. (2022). Coping during the COVID-19 pandemic
among young adults experiencing homelessness and unstable housing: A qualitative
study. Public health nursing (Boston, Mass.), 10.1111/phn.13136. Advance online
publication. https://doi.org/10.1111/phn.13136
Gibbs, K. D., Loveless, J., & Crane, S. (2022). A guide to using technological
applications to facilitate systematic reviews. Worldviews on evidence-based nursing,
10.1111/wvn.12611. Advance online publication. https://doi.org/10.1111/wvn.12611
BOOKS AND CHAPTERS
Gibbs, K. D. & Jackson, A. (2022). Clinical Practice Guidelines. In S. Wallace & G.
Golukakrishnan (Eds.) Evidence-Based Medicine: From the Clinician and Educator
Perspective. Nova Science Publishers: Happuage, NY.
PRESENTATIONS
International
Gibbs, K. D. & Garey, A. (July 2020). Evolution of EBP Education in a Large Pediatric
& Women’s Academic Hospital System. Sigma Theta Tau International Conference,
Virtual (due COVID-19, previously scheduled at Abu Dhabi, United Arab Emirates).
Gibbs, K. D., Whisenant, M., Maliackal, A., Pawelek, E., Crane, S. (12-28 October
2021). Electronic Visualizations of Patient-Reported Outcome Measure Data: A
Systematic Review (virtual poster). International Society for Quality of Life Research
(ISOQOL) 28th Annual Conference, Virtual (due to COVID-19).
Klinepeter, E. Gibbs, K. D., Choate, J., Nelson Hall, T. (May 11-14, 2022). Family
Perspectives on Behavioral Health Hospitalizations for Children with Autism Spectrum
Disorder (poster). International Meeting for Autism Research; Austin, TX.
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PRESENTATIONS CONTINUED
National
Gibbs, K. D. (June 9-11, 2011). The Creation of a Continuing Education Program for
Nurses in Uganda (poster). Association of Community Health Nurse Educators, Chicago,
IL.
Gibbs, K.D., Crews, N., Hensch, L. (October 19-22, 2019). Guiding Safe Blood
Transfusion Practices with Evidence (poster). AABB Annual Meeting, San Antonio, TX.
Gibbs, K. D., Jones, J., LaMark, W., Abdul-Mooti, S., Bretz, L., Santa Maria, D.
(February 2, 2021). The impact of COVID-19 on substance use and mental health among
youth experiencing homelessness (poster). International AIDS Society COVID—19
Conference: Prevention.
Nguyen, L., Freeman, A., Kobina, A., Keough, C., Asaithambi, R., Hadvani, T., Parikh,
V. Gibbs, K., Wallace, S. A. (April 30-May 4, 2021) Needs Assessment of EvidenceBased Practice Skills for Pediatric Hospitalists and Nurses in Community Hospital
Settings. Pediatric Academic Societies. Electronic poster presentation.
Gibbs, K. D., Wilson, D., Corso, N., McMonigle, S. (April 27-30, 2022). Stronger Belief
in EBP is Associated with More Implementation and Higher Perceived Competencies
among Pediatric and Obstetric Nurses. Society for Pediatric Nurses Conference;
Anaheim, CA.
Masciale, M., Lopez, M., Carretero Murillo, M., Fredricks, K., Gibbs, K. D.,
Asaithambi, R. Haq, H., Bocchini, C. E. (April 21-25, 2022). Hospitalized and hungry: a
mixed methods study describing inpatient food insecurity among immigrant caregivers of
hospitalized children. Pediatric Academic Societies 2022; Denver, CO.
Masciale, M., Haq, H., Carretero Murillo, M., Gibbs, K. D., Asaithambi, R. Fredricks,
K., Espinoza-Candelaria, G., Lopez, M., Dominguez, J., Jaramillo, M. A., Bocchini, C. E.
(April 21-25, 2022). “Even Though the Cage is Made of Gold, It’s Still a Prison”: A
Qualitative Study of Immigrant Caregiver Barriers in Access to Care and Public Benefit
Support in the United States. Pediatric Academic Societies 2022; Denver, CO.
Crane, S., Pieper, S., Gibbs, K. D. (September 15-17, 2022). “Approaches to Facilitate
Patient-Reported Outcome Symptom Assessments in Children and Adolescents with
Cancer.” Association of Pediatric Hematology/Oncology Nurses 46th Annual Convention;
West Palm Beach, FL.
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PRESENTATIONS CONTINUED
Local
Gibbs, K. D. (July 29, 2015). The Key to Unlocking the Evidence: How to Use Available
Literature to Answer Clinical Questions. Texas Children’s Hospital Nursing Professional
Day; Houston, TX.
Gibbs, K. D., Loveless, J., Jackson, A., Gordon, M., Graves, K. (July 14, 2016). PICO:
Asking the Well-Built Clinical Question. Texas Children’s Hospital Nursing Professional
Day, Houston, TX.
Gibbs, K. D., Porter, S., Loveless, J., Procido, C., Jackson, A. (September 13, 2016).
Evidence-Based Nursing Practice at the Bedside. Texas Children’s Hospital Nursing
Professional Day, Houston, TX.
Abela, K., Acorda, D., Cain, C., Gibbs, K. (June 9, 2017) Relationship of Food
Insecurity to Sociodemographic and Hospitalization Characteristics in Hospitalized
Children in Texas. (poster) University of Texas Health Science Center at Houston School
of Nursing Research Day, Houston, TX.
Gibbs, K. D., Hensch, L. (August 8, 2018). Pediatric Blood Transfusion Thresholds:
Evidence for Lower Hemoglobin Triggers. Texas Children’s Hospital Professional Day,
Houston, TX.
Abela, K., Acorda, D., Cain, C., Gibbs, K. D. (August 8, 2018). Relationship of Food
Insecurity to Sociodemographic and Hospitalization Characteristics in Hospitalized
Children in Texas. Texas Children’s Hospital Professional Day, Houston, TX.
Gibbs, K. D., Cain, C., Peters, L., Watson, E. (September 19, 2019). So You Want to Get
Your Master’s Degree, but You Don’t Want to be a Nurse Practitioner – A Panel
Discussion. Texas Children’s Hospital Professional Day, Houston, TX.
Loveless, J., Gibbs, K. D. (September 19, 2019). Improving Care via Evidence-Based
Clinical Standards. Texas Children’s Hospital Professional Day, Houston, TX.
Gibbs, K. D. (January 28, 2021). A Practical Guide to Systematic Review. University of
Texas Health Science Center at Houston Cizik School of Nursing Center for Nursing
Research Seminar Series, Houston, TX (invited).
Murillo, M. C., Lopez, M., Gibbs, K. D., Asaithambi, R., Fredricks, K., Haq, H.,
Espinoza-Candelaria, G., Dominguez, J., Jaramillo, M., Bocchini, C., Masciale, M. (May
20, 2021) “Even Though the Cage is Made of Gold, It’s Still a Prison”: A Qualitative
Study of Immigrant Caregiver Barriers in Access to Care and Public Benefit Support in
the United States. Center of Excellence in Health Equity, Training and Research Summer
Research Summit; Houston, TX. Award for Best Faculty/Staff-Led Project.
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PRESENTATIONS CONTINUED
Local
McMonigle, S., & Gibbs, K. D. (January 27, 2022). Stronger Belief in EBP is Associated
with More Implementation and Higher Perceived Competencies among Pediatric and
Obstetric Nurses. Texas Children’s Hospital Inaugural Student Nurse Grand Rounds,
Houston, TX (invited).
Acorda, D., Gibbs, K. D. (April 2, 2022). The pediatric nurse practitioners guide to find
evidence about clinical questions in an efficient way. Houston Chapter for the NAPNAP
Potpourri Conference; Houston, TX.
PROFESSIONAL MEMBERSHIPS
Organization

Role

Inclusive Dates

Sigma Theta Tau International

Member

2010-Present

Society for Pediatric Nurses

Member

2012-Present

American Nurses Association

Member

2015-2021, 2022-Present

Texas Nurses Association

Member

2015-2021, 2022-Present

GRADE Working Group

Member

2015-Present

Pediatric Trauma Society

Member

2017-Present

American Public Health
Association

Member

2009-2012, 2016-2018

PROFESSIONAL SERVICE
Editorial positions, boards, and peer review services
Associate Editor, Wong’s Nursing Care of Infants and Children, 12th edition (Planned
Publication Date: 2023)
Committee, educational, and volunteer service.
Co-chair, Texas Children’s Hospital Evidence-Based Practice and Research Nursing
Shared Governance Council, October 2021-September 2022
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TEACHING
Course

Institution

Role

Dates

Evidence-Based
Practice Course

Texas Children’s
Hospital

Co-instructor

2016, 2017, 2018

Evidence-Based
Nursing Practice
Course

Texas Children’s
Hospital

Co-instructor

2016

Essentials of
Evidence-Based
Nursing Practice

Texas Children’s
Global HOPE
Nursing Leadership
Program

Co-instructor

2020-2021

VOLUNTEERING
Nurse Volunteer, International Medical Corps, Haiti, March 2010
Public Health Nursing Volunteer, USS Iwo Jima Continuing Promise, Guyana; October
2010
Nurse Volunteer, Samaritan’s Purse; Titayen, Haiti; July 2011

